There was a time when my employer was contracted to do the programming for a phase of the US FBI's "Low Speed Fingerprint Imaging and Acquisition" system.
But in an Arena study published online this week in the journal Circulation: Cardiovascular Imaging, evaluation of over 5, 200 patients in phase 3 trials of 52 weeks of lorcaserin (10 mg, twice daily) or placebo showed only a slight difference in heart valve problems: 2.04% for placebo and 2.37% for lorcaserin.
Functional-imaging studies of the brain have revealed another tantalizing clue: During the aura phase, a wave of electrical activity sweeps over the outer, furrowed layer of the brain known as the cortex, at a pace of 2 to 3 millimeters per minute.